John Lesser Minneapolis Heart Institute Foundation

John Lesser, MD, FSCCT, FSCMR

Cardiologist

Dr. Lesser has published more than 100 articles, abstracts, CDs and books. He is the past President of the Society of Cardiovascular CTs (SCCT) Board of Directors where he served as Chairman of the Accreditation, Certification, and Guidelines Committee. He holds professional memberships as a fellow with the American College of Cardiology (ACC) and as a member of the American Heart Association (AHA), the Society for Cardiac Angiography and Intervention (SCAI) and the Society of Cardiovascular Magnetic Resonance (SCMR). He is on the Board of Directors with the Intersocietal Commission for CT Accreditation of Laboratories as well as the Credentialing and Certification Board for Cardiovascular CT.

Back to Valve Team

Professional Interests:

Catheterization, cardiac
Arrhythmia, cardiac
Cardiac electrophysiology
Preventive cardiology
Cardiac pacemaker, artificial
Echocardiography
Myocardial biopsy
Teleheart
CT and MRI

Give the Gift of Hope

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.